A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Trial Details

NCT ID
NCT07297329
Phase
PHASE3
Sponsor
Sinocelltech Ltd.
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • SCTC21C
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Newly diagnosed multiple myeloma (IMWG criteria) not eligible for transplant.
  • Evidence of measurable disease.
  • With adequate organ function and hematological parameters.
  • Contraception，and during the study period and for 5 months after the last dose, all subjects must not donate reproductive cells.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →